title: Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial.
abstract: OBJECTIVE
  The objective of this study was to examine whether statin therapy is associated with enhanced endothelium-dependent vascular function, improved pulmonary function and reduced systemic inflammation in patients with chronic obstructive pulmonary disease (COPD).
  
  
  METHODS
  This randomized, placebo-controlled, double-blind, parallel trial including patients with COPD was performed at two University hospitals in Norway.
  Patients with stable COPD (n = 99) were assigned randomly to receive rosuvastatin 10 mg (n = 49) or matching placebo (n = 50) once daily for 12 weeks. The primary outcome measure was change in endothelium-dependent vascular function measured using peripheral arterial tonometry and expressed as the reactive hyperaemia index. Secondary end-points were change in pulmonary function, as assessed by forced expiratory volume in 1 s (FEV1) and FEV1/forced vital capacity (FVC), and change in the circulating levels of the inflammatory markers interleukin-6 (IL6) and high-sensitivity C-reactive protein (hsCRP).
  
  
  RESULTS
  In the overall study population, no significant between-group difference in change in endothelium-dependent vascular or pulmonary function was observed. Rosuvastatin therapy was associated with a reduction in hsCRP (-20% vs. 11%, P = 0.017) and an attenuation of the rise in IL6 concentration (8% vs. 30%, P = 0.028) compared with placebo. In a prespecified subgroup analysis of patients with a supra-median circulating hsCRP concentration (>1.7 mg L(-1) ), rosuvastatin was associated with improved endothelium-dependent vascular function (13% vs. 2%, P = 0.026).
  
  
  CONCLUSIONS
  In stable COPD patients without the standard indications for statin therapy, rosuvastatin treatment is associated with a significant attenuation of systemic inflammation and improvement in endothelial-dependent vascular function in patients with evidence of systemic inflammation.
authors.affiliation: Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.|Center for Heart Failure Research and KG Jebsen Cardiac Research Centre, University of Oslo, Oslo, Norway.
authors.forename: A
authors.initials: A
authors.lastname: Neukamm
authors.affiliation: Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.|Center for Heart Failure Research and KG Jebsen Cardiac Research Centre, University of Oslo, Oslo, Norway.
authors.forename: A D
authors.initials: AD
authors.lastname: Høiseth
authors.affiliation: Center for Heart Failure Research and KG Jebsen Cardiac Research Centre, University of Oslo, Oslo, Norway.|Department of Pulmonology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
authors.forename: G
authors.initials: G
authors.lastname: Einvik
authors.affiliation: Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway.|Section for Thoracic Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway.
authors.forename: S
authors.initials: S
authors.lastname: Lehmann
authors.affiliation: Center for Heart Failure Research and KG Jebsen Cardiac Research Centre, University of Oslo, Oslo, Norway.|Unit of Medical Biochemistry, Division of Diagnostics and Technology, Akershus University Hospital, Lørenskog, Norway.
authors.forename: T-A
authors.initials: TA
authors.lastname: Hagve
authors.affiliation: Center for Heart Failure Research and KG Jebsen Cardiac Research Centre, University of Oslo, Oslo, Norway.|Department of Pulmonology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
authors.forename: V
authors.initials: V
authors.lastname: Søyseth
authors.affiliation: Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.|Center for Heart Failure Research and KG Jebsen Cardiac Research Centre, University of Oslo, Oslo, Norway.
authors.forename: T
authors.initials: T
authors.lastname: Omland
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000503:physiopathology*; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D005541:Forced Expiratory Volume; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007249:Inflammation / Q000503:physiopathology; D015850:Interleukin-6 / Q000097:blood; D008168:Lung / Q000503:physiopathology; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D014797:Vital Capacity
chemical_list: D015415:Biomarkers; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D015850:Interleukin-6; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein
keywords: chronic obstructive pulmonary disease; endothelial function; hydroxymethylglutaryl-CoA reductase inhibitors; inflammation; pulmonary disease; randomized controlled trial